Mirabegron settlement costs and competition
The $90 million settlement (with $75 million amortized) will impact profitability, and potential generic entrants could erode market share.
high · analyst_question
Lupin Ltd — Q3 FY26
Lupin delivered a strong Q3 FY26 with revenue of ₹7,168 crore (+24% YoY) and EBITDA margin of 31.1% (+681 bps YoY), driven by broad-based growth across regions.
bullish
high
✓ Verified against BSE filing
Risk Intelligence
Material risks this quarter
Concise cards keep the risk register scannable while preserving evidence-level context in the underlying quarter data.
Risks
US base business price erosion
Low single-digit price erosion in the US base business persists, which could offset volume gains if new product launches slow.
medium · management_commentaryBiosimilar market competition
Increasing competition in biosimilars, including PBM private labels, could pressure margins despite Lupin's cost advantage.
medium · analyst_questionElixa development delays
The respiratory product Elixa has faced development delays; management expects material progress only in calendar 2026.
low · analyst_question